Legut, Mateusz http://orcid.org/0000-0002-8810-6971
Gajic, Zoran http://orcid.org/0000-0002-8672-3757
Guarino, Maria
Daniloski, Zharko http://orcid.org/0000-0002-3453-0849
Rahman, Jahan A. http://orcid.org/0000-0001-8755-5890
Xue, Xinhe
Lu, Congyi
Lu, Lu http://orcid.org/0000-0002-7343-7161
Mimitou, Eleni P. http://orcid.org/0000-0001-9737-6394
Hao, Stephanie http://orcid.org/0000-0002-1700-9699
Davoli, Teresa
Diefenbach, Catherine
Smibert, Peter http://orcid.org/0000-0003-0772-1647
Sanjana, Neville E. http://orcid.org/0000-0002-1504-0027
Article History
Received: 2 June 2021
Accepted: 1 February 2022
First Online: 16 March 2022
Competing interests
: The New York Genome Center and New York University have applied for patents relating to the screening methods, identified targets and OverCITE-seq. C.D. receives research funding from Fate Therapeutics and Bristol Myers Squibb. N.E.S. is an adviser to Vertex and Qiagen.